Four new medicines and three biosimilars recommended for approval in Europe
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended four new medicines and three biosimilars for approval at its November meeting.
The CHMP recommended granting a marketing authorization for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with hemophilia A, from CSL Behring, a subsidiary of Australia’ CSL Limited (ASX: CSL). The drug was approved by theUS Food and Drug Administration in May this year.
Vemlidy (tenofovir alafenamide) received a positive opinion from the CHMP for the treatment of chronic hepatitis B from US biotech firm Gilead Sciences (Nasdaq: GILD). The recommendation comes just a day after the US FDA approved the drug for marketing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze